Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Protara Therapeutics Inc
TARA
Healthcare
Biotechnology
Protara Therapeutics, Inc. is a clinical-stage biotechnology company, which is engaged in advancing transformative therapies for people with cancer and rare diseases. The Company’s portfolio includes its lead candidate, TARA-002, an investigational cell-based therapy in development for the treatment of non-muscle invasive bladder cancer (NMIBC) and lymphatic malformations (LMs). The Company is...
evaluating TARA-002 in an ongoing Phase II trial in NMIBC patients with carcinoma in situ (CIS) who are unresponsive or naive to treatment with Bacillus Calmette-Guerin (BCG), as well as a Phase II trial in pediatric patients with LMs. In addition, the Company is developing IV Choline Chloride, an investigational phospholipid substrate replacement for patients on parenteral nutrition who are otherwise unable to meet their choline needs via oral or enteral routes.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (NDAQ:TARA)
New Post
View:
Posts & Comments
Threaded Posts
(280)
•••
whytestocks
X
Post by
whytestocks
on Dec 05, 2024 10:01am
Protara Presenting Positive Results from the Ongoing Phase 2
News; $TARA Protara Presenting Positive Results from the Ongoing Phase 2 ADVANCED-2 Trial of TARA-002 at SUO2024-12-05 08:16:41 ET DENVER, Colo., Dec 05, 2024 ( 247marketnews.com )- Protara
...more
(17)
•••
leste3221
X
Post by
leste3221
on Dec 05, 2024 9:08am
Protara vs Theralase
to evaluate whether Theralase or Protara Therapeutics would generate the most returns, we need to consider several financial and strategic factors: 1. Pipeline and Clinical Advancements
...more
Options Trading for Retiring: Cash flow in Your Golden years
posted Dec 07, 2024 9:00am by
Bank of Montreal
-
|
To maintain a plan for retiring comfortably, several key strategies must be kept in mind so retirees can continue generating income. These can include covered calls, cash secured puts, selling put-spreads, and buy-write strategies. BMO’s enhanced InvestorLine platform has industry-leading tools and capabilities specifically designed to empower options traders with access to a wealth of educational content. ...read more
(280)
•••
whytestocks
X
Post by
whytestocks
on Dec 03, 2024 1:15pm
Protara Therapeutics to Host Conference Call and Webcast to
Breaking News: $TARA Protara Therapeutics to Host Conference Call and Webcast to Review New Interim Data from Phase 2 ADVANCED-2 Trial of TARA-002 in Patients with NMIBC on Thursday, December 5
...more
(9)
•••
MikeTester
X
Post by
MikeTester
on Aug 02, 2024 8:19am
Protara Therapeutics, Inc. (NASDAQ:TARA): A Promising Biopha
https://beyondspx.com/2024/08/01/protara-therapeutics-inc-nasdaqtara-a-promising-biopharmaceutical-company-advancing-transformative-therapies/
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >
Featured News Links
Are PGM mining stocks an attractive area for your next portfolio allocation?